CellCarta Adds Tempus to CDx Commercialization Lab Network

Rhea-AI Summary

CellCarta announced a strategic collaboration with Tempus AI (NASDAQ: TEM), adding Tempus as the second commercial laboratory partner in CellCarta's CDx Commercialization Lab Network, alongside Sonic Healthcare USA. The partnership focuses on oncology and aims to streamline the path from companion diagnostic (CDx) development and regulatory approval to commercial use in U.S. oncology practice.

According to CellCarta, Tempus will use Tempus Hub to support provider test ordering, route samples to CellCarta for testing, and return results to physicians. The Lab Network is a component of CellCarta's four-stage CDx Accelerator Model (Build, Validate, Launch, Transfer), designed to give biopharma sponsors flexible entry points and commercialization pathways for centralized oncology CDx.

Positive

• Tempus added as second CDx commercialization partner in CellCarta network, focused on U.S. oncology practice
• Integration of Tempus Hub enables provider ordering, sample routing to CellCarta, and result return to physicians
• Access to CellCarta CDx Accelerator Model offers sponsors structured stages from assay development to commercial launch

Negative

• None.

Market Context

The Personalis announcement was followed by a -7.74% 24-hour reaction, adding a cautious platform co...

Analysis

The Personalis announcement was followed by a -7.74% 24-hour reaction, adding a cautious platform comparison to this partnership. Net selling by insiders remains a risk factor to monitor alongside execution of the network expansion.

Key Figures

Commercial laboratory partners: second commercial laboratory partner Accelerator stages: four stages

2 metrics

Commercial laboratory partners second commercial laboratory partner CellCarta's CDx Commercialization Lab Network

Accelerator stages four stages CDx Accelerator Model

Historical Context

5 past events · Latest: Jul 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Pharmacogenomics launch	Positive	-4.1%	National launch of OneOme testing integrated into Tempus's precision medicine ecosystem
Jul 20	Acquisition agreement	Positive	-7.7%	Agreement to acquire Personalis for $1.5 billion enterprise value
Jul 16	AI study publication	Positive	-6.4%	Published real-world results supported AI-assisted prostate biopsy reporting
Jul 09	Earnings date notice	Neutral	+7.4%	Scheduled release of second-quarter 2026 financial results
Jun 25	Research collaboration	Positive	+5.6%	Collaboration to study rare angiosarcoma using de-identified clinical records

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The stock declined after the three most recent positive operating or strategic announcements, while the earlier partnership announcement coincided with a gain.

Key Terms

cdx, companion diagnostic, immunohistochemistry, ivd

4 terms

cdx medical

"support oncology-focused access within CellCarta's CDx Accelerator Model."

A CDx (companion diagnostic) is a medical test that identifies which patients are likely to benefit from, or be harmed by, a specific prescription drug. Think of it like a key that tells doctors which lock (patient) matches a particular medicine, enabling more precise treatment choices; for investors, CDx tests can be crucial because regulatory approval and commercial uptake of a therapy often depend on the availability and performance of its companion diagnostic, affecting a drug’s market size and revenue timing.

companion diagnostic medical

"CellCarta will include Tempus in its CDx Commercialization Lab Network"

A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

immunohistochemistry medical

"performs centralized immunohistochemistry (IHC) and tissue-based testing."

Immunohistochemistry is a laboratory method that uses labelled antibodies to highlight specific proteins inside thin slices of tissue, producing visible color where those proteins are present—like using colored highlighters to mark words on a page. Investors care because it provides concrete evidence about whether a drug hits its intended target, whether a diagnostic test works, and how a treatment affects tissues, all of which can affect clinical success, regulatory approval, and market value.

ivd regulatory

"through additional laboratories or an IVD kitted solution."

IVD stands for in vitro diagnostic — tests, instruments and kits that analyze samples taken from the body (blood, saliva, tissue) outside the body, such as lab assays or home pregnancy tests. Investors watch IVDs because they drive recurring sales, depend on regulatory approval and insurance coverage to reach markets, and differences in accuracy, cost or availability can quickly affect a maker’s revenue and legal risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.

MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network's second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors.

Within the CellCarta network, the collaboration gives biopharma sponsors a more direct route from companion diagnostic development and regulatory approval to commercial use in U.S. oncology practice. CellCarta develops and validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus Hub, routing sample testing to CellCarta and transmitting results back to ordering healthcare providers.

Tempus joins Sonic Healthcare USA as the second member of CellCarta's CDx Commercialization Lab Network, expanding the network's specialized oncology capabilities alongside Sonic's broad clinical and anatomic pathology reach across multiple disease areas. The Lab Network is part of CellCarta's CDx Accelerator Model, a flexible and modular framework organized around four stages: Build, Validate, Launch, and Transfer. Sponsors can engage CellCarta at the stage that fits their program—from assay development and validation through clinical deployment and regulatory submission. Following approval, CellCarta activates its Commercialization Lab Network partners, such as Tempus and Sonic, to support commercial launch strategies.

"Tempus materially strengthens the oncology dimension of our commercialization model," said Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta. "Sponsors can develop and validate a companion diagnostic at CellCarta, pursue a single-site approval strategy through our flexible and modular CDx Accelerator Model, and then use an established oncology diagnostics platform to support physician access and ordering. This connects regulatory execution with the realities of commercial launch."

"Biopharma sponsors should not have to choose between the speed and control of a centralized CDx strategy and a credible path to physicians and patients," said Christopher Ung, Chief Scientific Business Officer of CellCarta. "Adding Tempus to our network creates a powerful route into U.S. oncology practice. It gives sponsors a practical commercialization channel from a company that oncologists already know and use, while CellCarta maintains continuity from development and regulatory approval through testing."

CellCarta launched its CDx Commercialization Lab Network to address a common gap in companion diagnostic programs: securing regulatory approval does not by itself create the commercial infrastructure required for physicians to order a test and for patients to access it. The network connects CellCarta's development, regulatory, and testing capabilities with commercial laboratory partners that have established provider relationships and ordering channels.

CellCarta intends to continue expanding the network by geography, therapeutic area, and commercial capability. The company's objective is to give sponsors multiple pathways for launching centralized companion diagnostics while retaining flexibility for later expansion through additional laboratories or an IVD kitted solution.

To learn more about CellCarta's companion diagnostic capabilities, visit https://cellcarta.com/cdx-services/ 

About CellCarta

CellCarta is a global CRO laboratory supporting the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides biomarker testing services and customized solutions to pharmaceutical and biotechnology companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X.

Media Contacts

Stéphanie Bussières-Marmen, PhD
Director, Global Marketing
media@cellcarta.com

Melanie Williams
Senior Marketing Communications Specialist, Supreme Optimization
melanie.williams@supremeopti.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellcarta-adds-tempus-to-cdx-commercialization-lab-network-302844793.html

SOURCE CellCarta

FAQ

What does the CellCarta and Tempus AI (NASDAQ: TEM) collaboration announced on August 6, 2026 involve?

The collaboration adds Tempus to CellCarta’s CDx Commercialization Lab Network as its second commercial lab partner, focused on oncology. According to CellCarta, Tempus will support provider ordering via Tempus Hub, route samples to CellCarta for testing, and transmit results back to physicians.

How could joining CellCarta’s CDx Commercialization Lab Network impact Tempus AI (TEM) in oncology diagnostics?

The partnership positions Tempus within CellCarta’s oncology-focused CDx commercialization ecosystem, potentially increasing its role in U.S. oncology testing workflows. According to CellCarta, Tempus provides an established oncology diagnostics platform that sponsors can use for physician access, ordering, and result delivery after CDx regulatory approval.

How will Tempus Hub be used in CellCarta’s CDx Accelerator Model for oncology companion diagnostics?

Tempus Hub will facilitate provider test ordering, route samples to CellCarta, and return CDx results to ordering physicians. According to CellCarta, this links its centralized IHC and tissue-based testing capabilities with Tempus’s digital ordering channel, supporting practical implementation in U.S. oncology practice after regulatory approval.

What is CellCarta’s CDx Accelerator Model mentioned in the Tempus AI (TEM) collaboration, and what are its stages?

CellCarta’s CDx Accelerator Model is a flexible framework for companion diagnostics organized into four stages: Build, Validate, Launch, and Transfer. According to CellCarta, sponsors can engage at any stage, from assay development and validation through clinical deployment, regulatory submission, and subsequent commercialization via network partners like Tempus.

Why did CellCarta add Tempus AI (TEM) as the second member of its CDx Commercialization Lab Network?

CellCarta added Tempus to materially strengthen the oncology dimension of its commercialization model. According to CellCarta, Tempus brings a recognized oncology diagnostics platform, giving biopharma sponsors a practical commercialization channel into U.S. oncology practice, complementing Sonic Healthcare USA’s broader multi-disease pathology reach.

How does the CellCarta–Tempus AI (TEM) agreement benefit biopharma sponsors developing companion diagnostics?

Biopharma sponsors gain a single route from CDx development and regulatory approval at CellCarta to commercial use via Tempus and Sonic. According to CellCarta, sponsors can maintain centralized CDx speed and control while accessing established laboratory platforms and provider ordering channels for U.S. physician and patient access.